Anton I Rosenbaum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8109828/publications.pdf

Version: 2024-02-01

623188 752256 1,014 19 14 20 citations g-index h-index papers 21 21 21 1448 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|-----------|----------------|
| 1 | The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Science Translational Medicine, 2022, 14, eabl8124. | 5.8 | 143 |
| 2 | Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics. BioDrugs, 2022, 36, 181-196. | 2.2 | 8 |
| 3 | Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Chiral Assays, Oligos; Nanome | Qq1.1 0.7 | /84314 rgBT /C |
| 4 | Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 3602-3609. | 3.2 | 20 |
| 5 | Characterization of Antibody–Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM. Analytical Chemistry, 2021, 93, 6135-6144. | 3.2 | 17 |
| 6 | Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase $1\ \rm trial.$ Science Translational Medicine, 2021, $13\ \rm ,$. | 5.8 | 16 |
| 7 | First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Molecular Cancer Therapeutics, 2021, 20, 1442-1453. | 1.9 | 38 |
| 8 | Differences in levels of phosphatidylinositols in healthy and stable Coronary Artery Disease subjects revealed by HILIC-MRM method with SERRF normalization. PLoS ONE, 2021, 16, e0252426. | 1.1 | 3 |
| 9 | Targeted oral peptide delivery using multi-unit particulates: Drug and permeation enhancer layering approach. Journal of Controlled Release, 2021, 338, 784-791. | 4.8 | 14 |
| 10 | LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 3005-3014. | 1.1 | 6 |
| 11 | Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Scientific Reports, 2021, 11, 22521. | 1.6 | 27 |
| 12 | Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody–Drug Conjugate. Analytical Chemistry, 2020, 92, 11135-11144. | 3.2 | 15 |
| 13 | Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2. Antibodies, 2019, 8, 11. | 1.2 | 40 |
| 14 | ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. Antibodies, 2018, 7, 41. | 1.2 | 24 |
| 15 | Niemannâ€Pick type C disease: molecular mechanisms and potential therapeutic approaches. Journal of Neurochemistry, 2011, 116, 789-795. | 2.1 | 205 |
| 16 | Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5477-5482. | 3.3 | 229 |
| 17 | Thiadiazole Carbamates: Potent Inhibitors of Lysosomal Acid Lipase and Potential Niemannâ'Pick Type C Disease Therapeutics. Journal of Medicinal Chemistry, 2010, 53, 5281-5289. | 2.9 | 75 |
| 18 | Investigation of <i>N</i> -Aryl-3-alkylidenepyrrolinones as Potential Niemannâ^Pick Type C Disease Therapeutics. Journal of Medicinal Chemistry, 2009, 52, 6494-6498. | 2.9 | 29 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Chemical screen to reduce sterol accumulation in Niemann–Pick C disease cells identifies novel lysosomal acid lipase inhibitors. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1155-1165. | 1.2 | 50 |